ClinicalTrials.Veeva

Menu

Effect of Visual Retraining After Stroke (urochester)

University of Rochester logo

University of Rochester

Status

Active, not recruiting

Conditions

Vision; Loss, Both Eyes
Hemianopia
Hemianopia Homonymous
Vision Loss Partial
Cortical Blindness
Quadrantanopia
Stroke - Occipital Infarction
Stroke, Ischemic

Treatments

Device: Training in the Blind Field

Study type

Interventional

Funder types

Other

Identifiers

NCT06121219
STUDY00008697

Details and patient eligibility

About

This project is intended to collect data using standard clinical tests and psychophysics to quantify the effect of visual cortical damage on the structure of the residual visual system, visual perception, spatial awareness, and brain function. The investigators will also assess the effect of intensive visual retraining on the residual visual system, processing of visual information and the use of such information in real-world situations following damage. This research is intended to improve our understanding of the consequences of permanent visual system damage in humans, of methods that can be used to reverse visual loss, and of brain mechanisms by which visual recovery is achieved.

Enrollment

100 patients

Sex

All

Ages

21 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Cortically Blind Subjects

Inclusion:

  • Between 21 and 80 years of age
  • Residents of the United States or Canada
  • Unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range (21-75 years)
  • Reliable visual field defects in both eyes as measured by Humphrey, MAIA, Goldmann, and/or equivalent perimetry, large enough to enclose a 5-deg diameter visual stimulus.
  • Able to fixate on visual targets reliably for 1000ms
  • Must have a home computer (desktop or laptop) and reliable internet access
  • Willing, able, and competent to provide informed consent
  • Normal cognitive abilities, able to understand written and oral instructions in English, and competent and responsible adults in order to complete the visual training at home, independently, as instructed, for several months.

Exclusion:

  • Past or present eye disease interfering with visual acuity
  • BCVA worse than 20/40 in either eye
  • Damage to the dorsal Lateral Geniculate Nucleus
  • Diffuse whole brain degenerative processes
  • History of traumatic brain injury
  • Any other brain damage deemed by study staff to potentially interfere with training ability or outcome measures
  • Documented history of drug/alcohol abuse
  • Currently taking neuroactive medications which would impact training, as determined by PI
  • Presence of cognitive or seizure disorders
  • One-sided attentional neglect
  • Subjects who lack the competence or are otherwise unable to perform the visual training exercises as directed.

Control Subjects (n = 50)

Inclusion:

  • Between 21 and 80 years of age
  • Report no history of neurological disorder.
  • Competent and responsible, as determined by the Principal Investigator.

Exclusion:

  • Presence of damage to the visual system
  • Presence of an active disease process involving their nervous system.
  • Cognitive or seizure disorders
  • Best corrected visual acuity worse than 20/40 in either eye
  • Presence of vision field loss from ocular disease or disorder

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 2 patient groups

Experimental: Cortically Blind (CB) Subjects
Experimental group
Description:
Cortically Blind subjects will be enrolled to perform a daily home visual training task.
Treatment:
Device: Training in the Blind Field
Normative Comparator: Control Subjects
No Intervention group
Description:
Healthy control subjects will be recruited to collect normative data by which to compare test results from CB subjects. No home training will be asked.

Trial contacts and locations

1

Loading...

Central trial contact

Chrys Callan

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems